

**Ref: ADL/SE/2024-25/07**  
**April 23, 2024**

To,  
Listing/ Compliance Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001  
**BSE CODE: 524348**

To,  
Listing/ Compliance Department  
**National Stock Exchange of India Limited,**  
“Exchange Plaza”, Plot No. C/1,  
G Block Bandra - Kurla Complex,  
Bandra (East), Mumbai – 400051  
**NSE SYMBOL: AARTIDRUGS**

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We wish to inform you that the United States Food and Drug Administration (“US FDA”) has inspected the Formulations (Oncology) manufacturing facility of our Subsidiary (Pinnacle Life Science Private Limited) at Baddi, Himachal Pradesh from 16<sup>th</sup> to 22<sup>nd</sup> of April 2024.

On conclusion of the inspection, the company has received 5 inspectional observations in Form 483, where none of the observations are related to Data Integrity. The company will work closely with US FDA in resolving all points.

There is no impact on financial, operation or other activities of the Company pursuant the observations received.

This is for your information and records.

Thanking you,

Yours faithfully,

**FOR AARTI DRUGS LIMITED**

**RUSHIKESH DEOLE**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**  
ICSI M. No.: F12932